Home › Funds › VIKING GLOBAL INVESTORS LP › BMRN
VIKING GLOBAL INVESTORS LP position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
VIKING GLOBAL INVESTORS LP reported holding 7,173,173 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$430.4M, representing 1.32% of its reported portfolio and ranking #34 among its reported holdings. VIKING GLOBAL INVESTORS LP has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How VIKING GLOBAL INVESTORS LP's BMRN position evolved
VIKING GLOBAL INVESTORS LP first disclosed a stake in BMRN in Q3 2023 at 4,215,456 shares (US$373.0M). The position peaked in Q1 2025 at 10,800,059 shares, worth US$763.5M. Across 13 filings, VIKING GLOBAL INVESTORS LP increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 7,173,173 shares valued at US$430.4M — a reduction of -443,390 shares quarter over quarter.. Notable position changes include a 31% increase in Q1 2024 (shares fell 6% over the following quarter), a 38% increase in Q3 2024 (shares fell 6% over the following quarter), a 32% trim in Q3 2025 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.22M | $372.98M | New |
| Q4 2023 | 4.89M | $471.44M | Add |
| Q1 2024 | 6.42M | $560.40M | Add |
| Q2 2024 | 7.06M | $581.54M | Add |
| Q3 2024 | 9.75M | $685.56M | Add |
| Q4 2024 | 10.51M | $690.86M | Add |
| Q1 2025 | 10.80M | $763.46M | Add |
| Q2 2025 | 12.29M | $675.50M | Add |
| Q3 2025 | 8.32M | $450.73M | Reduce |
| Q4 2025 | 6.04M | $358.78M | Reduce |
| Q1 2026 | 7.06M | $398.94M | Add |
| Q2 2026 | 7.62M | $435.82M | Add |
| Q3 2026 | 7.17M | $430.39M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 26 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$899.3M), Viking Global Investors (US$435.8M), Deep Track Capital, LP (US$382.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.99M sh · $899.34M · Q3 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- Deep Track Capital, LP 6.37M sh · $382.46M · Q3 2026
- Vestal Point Capital, LP 5.53M sh · $331.50M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 2.03M sh · $121.51M · Q3 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $109.58M · Q3 2026
More on VIKING GLOBAL INVESTORS LP
FAQ
How long has VIKING GLOBAL INVESTORS LP held BMRN?
VIKING GLOBAL INVESTORS LP has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is VIKING GLOBAL INVESTORS LP's current position in BMRN?
As of Q3 2026, VIKING GLOBAL INVESTORS LP holds 7.17M shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $430.39M, representing 1.32% of its reported portfolio and ranking #34.
Has VIKING GLOBAL INVESTORS LP been buying or selling BMRN?
In the latest 13F filing (Q3 2026), VIKING GLOBAL INVESTORS LP reduced its position in BMRN. The position peaked in Q1 2025 at 10.80M shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, Deep Track Capital, LP, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.